Metraipolis › archive › dc_a550f7f23ccc

Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine — Europe PMC PMID:40923371

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40923371
DOI
10.1002/cam4.71167
License (as archived)
solo-consultazione
Archived
2026-11-10T05:26:24.024Z
SHA-256 of the archived text
3ff14c0f5a5c9f4ccae25c83539c69b50778bdb1e3705564166d54e8a1a5c0b1
Stable URL of this page
https://metraipolis.com/documento/dc_a550f7f23ccc

How to cite

Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine — Europe PMC PMID:40923371 — Europe PMC (en), https://europepmc.org/article/MED/40923371 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a550f7f23ccc (Metraipolis archive dc_a550f7f23ccc, sha256 3ff14c0f5a5c9f4ccae25c83539c69b50778bdb1e3705564166d54e8a1a5c0b1)
BibTeX
@misc{dca550f7f23ccc,
  title = {Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine — Europe PMC PMID:40923371},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40923371},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a550f7f23ccc; sha256 3ff14c0f5a5c9f4ccae25c83539c69b50778bdb1e3705564166d54e8a1a5c0b1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40923371. Agents can read the archived copy with the MCP tool read_document.